Press Releases – IOVANCE Biotherapeutics, Inc.

Mar 01, 2023 Iovance Biotherapeutics to Present at Upcoming Conferences

SAN CARLOS, Calif. , March 01, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences: H.C.

View
Feb 28, 2023 Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

First Biologics License Application (BLA) Submission on Track to Complete in 1Q23 SAN CARLOS, Calif. , Feb. 28, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating

View
Feb 21, 2023 Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023

SAN CARLOS, Calif. , Feb. 21, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 .

View
Jan 23, 2023 Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates

Acquisition of Worldwide Rights to Proleukin ® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3 Confirmatory Study in Frontline Advanced (Metastatic or Unresectable) Melanoma Positive Clinical Data in

View